Find Therapeutics Begins Patient dosing in Phase 1 Trial of FTX-101

Find Therapeutics, a biopharmaceutical company in the clinical stage, has started administering doses of FTX-101 in its phase 1 clinical trial involving healthy participants. FTX-101 is a novel therapeutic peptide that controls the Plexin A1/Neuropilin 1 transmembrane receptor complex in the brain to support remyelination. After finishing phase 1 clinical trial, Find intends to explore the application of FTX-101 in patients with chronic optic neuropathy - a prolonged disorder caused by demyelination in the visual pathways of the brain and optic nerve, leading to severe impacts on vision acuity and perception.

The initial human study phase 1 will evaluate how safe, tolerable, and the pharmacokinetics of FTX-101 are in healthy volunteers when administered. The research is starting after receiving authorization from the US Food and Drug Administration earlier this year. The clinical trial is divided into two sections. Part 1 involves 40 subjects in a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study with either FTX-101 or placebo, while Part 2 consists of a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study with 24 subjects receiving FTX-101 or placebo.

This study's commencement is a major milestone for our company and those with chronic optic neuropathy. In this research, we will expand on the extensive preclinical evidence that shows FTX-101's impact in autoimmune disease models. Implementing this kind of therapy would be a significant advancement in developing the initial intervention to enhance the well-being of individuals suffering from chronic optic neuropathy. We are excited to present findings from this study by mid-2025.